Some industries are immune to economic recessions, healthcare for instance.
If you fall sick, won’t you visit a doctor and get all the prescribed tests done, no matter how costly they are?
Indeed, early diagnosis is extremely crucial in treating dreaded diseases.
No wonder well-equipped diagnostic companies employing qualified professionals are always flooded with patients.
And they make good money if competent managements run them.
Would you like to become a part owner of any such diagnostic company?
Well, there’s an open offer for you.
Metropolis Healthcare Limited has come up with an Initial Public Offer (IPO).
Should you subscribe?
Yes, is the answer!
Metropolis is one of India’s leading diagnostics companies. It has a widespread presence across 18 states in India. It enjoys a leadership position in the western and southern regions.
Established in 1981, Metropolis operates through 3,480 clinical laboratories, 1,130 patient touch points and 9,552 institutional touch points covering 197 cities.
Metropolis offers a comprehensive range of clinical laboratory tests and profiles, which are used for prediction, early detection, diagnostic screening, confirmation and/or monitoring of the disease. It also offers analytical and supports services to clinical research organisations for their clinical research projects.
In FY18, it conducted approximately 16 million tests from approximately 7.7 million patient visits.
Top line of Metropolis grew at 16% CAGR from Rs 474 crores in FY16 to Rs 643 crores in FY18. EBITDA rose 16.9% to Rs. 177 crores in FY18 from Rs 129.8.
(Source: Company, Ventura Research)
Read our detailed IPO note here.